CS-8958 Clinical Pharmacology study -Evaluation of intrapulmonary pharmacokinetics of CS-8958 and laninamivir after a single inhaled dose of CS-8958 in healthy Japanese subjects -

Trial Profile

CS-8958 Clinical Pharmacology study -Evaluation of intrapulmonary pharmacokinetics of CS-8958 and laninamivir after a single inhaled dose of CS-8958 in healthy Japanese subjects -

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 27 Jun 2017 Results presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics
    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top